Urteste S.A. (URT.WA)
PLN 92.8
(-1.28%)
PLN 92.8
(-1.28%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -5.58 Million PLN | -37.59% |
| 2022 | -4.05 Million PLN | -74.86% |
| 2021 | -2.32 Million PLN | -337.89% |
| 2020 | -530.22 Thousand PLN | -45.37% |
| 2019 | -364.73 Thousand PLN | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -1.33 Million PLN | -19.93% |
| 2024 Q2 | -554 Thousand PLN | 58.35% |
| 2023 Q4 | -1.1 Million PLN | 13.56% |
| 2023 Q1 | -1.42 Million PLN | -24.83% |
| 2023 Q2 | -1.76 Million PLN | -23.67% |
| 2023 Q3 | -1.28 Million PLN | 27.35% |
| 2023 FY | -5.58 Million PLN | -37.59% |
| 2022 Q1 | -962.28 Thousand PLN | -27.49% |
| 2022 FY | -4.05 Million PLN | -74.86% |
| 2022 Q4 | -1.14 Million PLN | -55.86% |
| 2022 Q3 | -734 Thousand PLN | 37.74% |
| 2022 Q2 | -1.17 Million PLN | -22.52% |
| 2021 Q4 | -754.8 Thousand PLN | -15.77% |
| 2021 Q3 | -652 Thousand PLN | -169.67% |
| 2021 Q2 | -241.77 Thousand PLN | 56.4% |
| 2021 Q1 | -554.58 Thousand PLN | 0.0% |
| 2021 FY | -2.32 Million PLN | -337.89% |
| 2020 Q2 | -237.56 Thousand PLN | 0.0% |
| 2020 FY | -530.22 Thousand PLN | -45.37% |
| 2019 FY | -364.73 Thousand PLN | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Bioceltix S.A. | -13.68 Million PLN | 59.189% |
| BIOTON S.A. | 2.27 Million PLN | 345.538% |
| Captor Therapeutics Spolka Akcyjna | -70.58 Million PLN | 92.086% |
| Mabion S.A. | 41.26 Million PLN | 113.536% |
| Molecure S.A. | -18.3 Million PLN | 69.489% |
| NanoGroup S.A. | -7.88 Million PLN | 29.2% |
| Pharmena S.A. | 28.94 Million PLN | 119.301% |
| Poltreg S.A. | -13.55 Million PLN | 58.778% |
| Pure Biologics Spólka Akcyjna | -35.69 Million PLN | 84.35% |
| Ryvu Therapeutics S.A. | -92.11 Million PLN | 93.936% |
| Synthaverse S.A. | 4.75 Million PLN | 217.402% |